OFORTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oforta, and what generic alternatives are available?
Oforta is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in OFORTA is fludarabine phosphate. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the fludarabine phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oforta
A generic version of OFORTA was approved as fludarabine phosphate by HIKMA on August 28th, 2003.
Summary for OFORTA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 18 |
Patent Applications: | 2,197 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OFORTA at DailyMed |
Recent Clinical Trials for OFORTA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bristol-Myers Squibb | Phase 1 |
Stand Up To Cancer | Phase 1 |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for OFORTA
US Patents and Regulatory Information for OFORTA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | OFORTA | fludarabine phosphate | TABLET;ORAL | 022273-001 | Dec 18, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OFORTA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | OFORTA | fludarabine phosphate | TABLET;ORAL | 022273-001 | Dec 18, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
Sanofi Aventis Us | OFORTA | fludarabine phosphate | TABLET;ORAL | 022273-001 | Dec 18, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OFORTA
See the table below for patents covering OFORTA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 136283 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 03053418 | ⤷ Try a Trial | |
New Zealand | 533701 | Ultrapure oral fludara formulation with a fast releasing active substance | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |